Plus Therapeutics Inc
PSTV
View Detailed Chart
0.416USD
-0.015-3.60%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
38.31MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-3.60%
5 Days
-7.09%
1 Month
-20.55%
6 Months
-18.67%
Year to Date
-63.86%
1 Year
-74.03%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated: 2025-09-19Key Insights
The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a good stock market performance and outperforming fundamentals, the technicals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
4
analysts
Buy
Current Rating
8.833
Target Price
+1949.02%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Company’s Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 2500.00% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 5.82M.
Overvalued
The company’s latest PE is -0.32, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 2.30M shares, decreasing 50.85% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 32.54K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.28.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Company’s Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.
Ticker SymbolPSTV
CompanyPlus Therapeutics Inc
CEODr. Marc H. Hedrick, M.D.
Websitehttp://www.plustherapeutics.com/
Related Instruments
+0.68%
+0.77%
-2.48%
-1.58%
-0.75%
-0.09%
+1.34%
-1.77%
-0.67%
-3.03%
-0.85%
-0.87%
-0.50%
+0.42%
-0.19%
-1.18%
-1.83%
0.00%
+0.30%
-3.72%
